Petrovax Pharm’s meningococcal vaccine localization project wins the Platinum Ounce Award

Petrovax Pharm’s project to localize production of a quadrivalent meningococcal vaccine has won the 26th All-Russian Platinum Ounce Award in the Business Project subcategory under Project of the Year. The award ceremony took place on April 16 in Moscow.

For the first time in Russia, a full-cycle technology transfer has been implemented for the production of a quadrivalent vaccine against meningococcal infection, including active substance synthesis. Total investment in the project exceeds RUB 3 billion, and the planned production capacity is more than 4 million doses per year.

The goal of the project is to fully meet the country’s demand for a meningococcal vaccine. Inclusion of the vaccine in the National Immunization Schedule will make it possible to protect the most vulnerable group, young children, from this extremely dangerous disease. In addition, the use of a domestic vaccine is expected to help reduce healthcare budget expenditures due to its lower cost compared with imported alternatives.

"The implementation of this project is an important step toward building an independent vaccine manufacturing infrastructure in Russia. Thanks to our deep expertise in immunobiology and strong production capabilities, we were able to complete it within a short timeframe. Recognition by the industry confirms both the significance and the demand for this project and, as we hope, will support the further inclusion of the vaccine in the National Immunization Schedule,"

said Mikhail Tsyferov, President of Petrovax Pharm.

Marketing authorization for the vaccine is expected in summer 2026.

Previous news

15 April 2026

Meningococcal infection steadily rising in Russia: experts demand urgent inclusion of vaccine into National immunization schedule

#Vaccination #MeningococcalInfection #NationalImmunizationSchedule #Immunoprophylaxis